179 related articles for article (PubMed ID: 29636930)
21. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
[TBL] [Abstract][Full Text] [Related]
24. Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?
Fitzal F; Turner SD; Kenner L
Open Biol; 2019 Apr; 9(4):190006. PubMed ID: 30939983
[TBL] [Abstract][Full Text] [Related]
25. An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Premji S; Barbieri A; Roth C; Rohren EM; Rivero G; Teegavarapu SP
Case Rep Hematol; 2022; 2022():4700787. PubMed ID: 35721802
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
27. Stage IV Breast Implant-associated Anaplastic Large-cell Lymphoma with Complete Pathologic Response to Neoadjuvant Chemotherapy.
Thibodeau R; Fan KL; Wehner PB
Plast Reconstr Surg Glob Open; 2019 Sep; 7(9):e2446. PubMed ID: 31942403
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
29. Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Rastogi P; Deva AK; Prince HM
Curr Hematol Malig Rep; 2018 Dec; 13(6):516-524. PubMed ID: 30345474
[TBL] [Abstract][Full Text] [Related]
30. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.
DeVita MD; Evens AM; Rosen ST; Greenberger PA; Petrich AM
J Natl Compr Canc Netw; 2014 Apr; 12(4):465-71. PubMed ID: 24717566
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab Vedotin in CD30+ Lymphomas.
Perini GF; Pro B
Biol Ther; 2013; 3(1):15-23. PubMed ID: 24392301
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
Garnock-Jones KP
Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
[TBL] [Abstract][Full Text] [Related]
33. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.
Donato EM; Fernández-Zarzoso M; Hueso JA; de la Rubia J
Onco Targets Ther; 2018; 11():4583-4590. PubMed ID: 30122950
[TBL] [Abstract][Full Text] [Related]
35. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
[TBL] [Abstract][Full Text] [Related]
36. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
Sasapu A; Dunn ALJ; Gardner J; Wong HK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015
[TBL] [Abstract][Full Text] [Related]
37. Oncological Outcomes After Multidisciplinary Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).
O'Connell RL; Sharma B; El-Sharkawi D; Wotherspoon A; Attygalle AD; MacNeill F; Khan AA; Tasoulis MK
Ann Surg Oncol; 2023 Oct; 30(10):6170-6175. PubMed ID: 37454017
[TBL] [Abstract][Full Text] [Related]
38. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
39. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
40. Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
Popova TN; Radinov A; Stavrov K; Temelkova I; Terziev I; Lozev I; Lukanova D; Mangarov H; Wollina U; Tchernev G
Open Access Maced J Med Sci; 2018 Jul; 6(7):1275-1277. PubMed ID: 30087736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
